Arylsubstituted piperazines useful in the treatment of...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S210020, C514S210200, C514S217050, C514S252130, C514S253010, C514S254010, C514S254080, C540S200000, C540S354000, C540S362000, C540S451000, C540S481000, C540S524000, C540S598000, C544S230000, C544S360000, C544S372000, C544S373000

Reexamination Certificate

active

06890921

ABSTRACT:
This invention relates to a series of arylsubstituted piperazines, of Formula Ipharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the α-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.

REFERENCES:
patent: 4069336 (1978-01-01), Lange et al.
patent: 4560686 (1985-12-01), Nagano et al.
patent: 4841051 (1989-06-01), Shiozawa et al.
patent: 5380725 (1995-01-01), Abou-Gharbia et al.
patent: 5403847 (1995-04-01), Gluchowski et al.
patent: 5807856 (1998-09-01), Bock et al.
patent: 0 558 245 (1993-09-01), None
patent: 0 711 757 (1996-05-01), None
patent: 2 201 676 (1988-09-01), None
patent: 199858 (1990-03-01), None
patent: WO 8404302 (1984-11-01), None
patent: WO 9400442 (1994-01-01), None
patent: WO 9504049 (1995-02-01), None
A. Orjales et al.:“New (2-methoxyphenyl) piperazine derivativea as 5-HT-1A receptor ligands with reduced alpha-1-adrenergic activity. Synthesis and structure-affinity activity. Synthesis and structure-affinity relationships.” Journal of Medicinal Chemistry., vol. 38 No. 8, 1995, pp. 1273-1277, XP-002074046.
R.K. Raghupathi et al.: “Analogues of the 5-HT-1A serotonin antagonist 1-(2-methoxypenyl)-4-'4-(2-phthalimido)butyl!piperazine with reduced alpha-1-adrenergic affinity” Journal of Medicinal Chemistry, vol. 34, No. 8, 1991, pp. 2633-2638, XP002074047.
Breslin D, Fields DW, Chou TC, Marion DN, Kane M, Vaughan ED, and Felsen D (1993) Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate. J. Urol. 149:395-399.
Hatano A., Takahashi H, Tamaki M, Komeyama T, Koizumi T, and Takeda M 1994) Pharmacological evidence of a distinct α1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br. J. Pharmaocl. 1133:723-728.
Lepor H, Auerbach S, Puras-Baez A et al. (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperlasia. J. Urol. 148:1467-1474.
Hungarian Novelty Search Report, dated Nov. 6, 2002, for Hungarian Appln. No. P0100048.
Bruno JF, Whittaker J. Song J. and Bereiowitz M (1991) Molecular cloning and sequencing of a cDNA encoding a human α1A adrenergic receptor. Biochem. Biophys. Res. Commun. 179:1485-1490.
Byfund DB, Eikenberg DC, Heible JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR, and Trendelenburg U (1994) IV. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46: 121-136.
Carruthers SG (1994) Adverse effects of a α1-adrenergic blocking drugs. Drugs Safety 11:12-20.
Faure C. Gouthier C, Langer SZ, and Graham D (1995) Quantification of α1-adrenergic subtypes in human tissues by competitive RT-PCR anlaysis. Biochem Biophsy. Res. Commun.213:935-943.
Flavahan NA and VanHoutte PM (1986) α1-Adrenergic subclassification in vascular smooth muscle. Trends Pharmacol. Sci. 7:347-349.
Ford APDW, Arredondo NF, Blue DR, Bonhaus DW, Jasper J, Kava MS, Lesnick J, Pfister JR, Shieh IA, Vimont, RL, Williams TJ, McNeal JE, Stamey TA, and Clarke DE (1996) RS-17053 (N-[2-(2-Cyclopropylmethoxyphenoxy)ethyl]-5-chloro-a, a-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective α1A-adrenoceptor antagonist, displays low affinity for functional α1-adrenoceptors in human prostate: Implications for adrenoceptor classification. Mol. Pharmacol. 49: 209-215.
Forray C, Band JA, Wegzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Brancheck TA, and Gluchowski C (1994) The α1-adrenergic receptor that mediates smooth muscle contraction in human prostrate has the pharmacological properties of the cloned human α1c subtype. Mol. Pharmacol. 45: 703-708.
Gormley G, Stoner E, Bruskewitz RC et al. (1992) The effect of finasteride in men with benign prostatic hyperplasia. N. Engl.J. Med.327: 1185-1191.
Harrison JK, Pearson WR, and Lynch KR (1991) Molecular characterization of α1- and α2- adrenoceptors. Trends Pharmacol. Sch. 12:62-67.
Hieble JP and Caine M (1986) Etiology of benign prostatic hyperplasia and approaches to pharmacological management Fed. Proc. 45: 2601-2603.
Hirasawa A, Horie K, Tanaka T, Takagaki K. Murai M, Yano J., and Tsujimoto G (1993) Cloning, functional expression and tissue distribution of human cDNA for the α1-adrenergic receptor. Biochem. Biophys. Res. Commun. 195: 902-909.
Holck MI, Jones CHM, and Haeusler G (1983) Differential interactions of cloridine and methoxamine with postsynaptic α-adrenoceptors of rabbit main pulmonary artery. J Cardiovasc. Pharm. 5: 240-248.
Lepor H and Rigaud G (1990) The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J. Urol. 143:533-537.
Lepor H (1995) α-Blockade for benign prostatic hyperplasia (BPH) J Clin. Endocrinol. Metab. 80:750-753.
Marshall I, Burt RP, Andersson PO, Chapple CR, Greensgrass PM, Johnson GI, and Wyllie MC (1992) Human α1c-adrenoceptor: functional characterisation in prostate. Br. J. Pharmacol. 107 (Proc. Suppl. Dec.): 327P.
Marshall I, Burt RP, and Chapple CR (1995) Noradrenaline contractions of human prostate mediated by α1A-(α1c-) adrenoceptor subtype. Br. J. Pharmacol. 115: 781-786.
Mebust WK, Hollgrewe HL, Cockett ATK, and Peters PC (1989) Transurethral prostatectomy: immediate and postoperative complication: a cooperative study of 13 participating institutions evaluating 3,885 patients J. Urol. 141:243-257.
Minneman KP, Han C and Abel PW (1988) Comparison of α1-adrenergic receptor subtypes distinguished by chloroethylchlonidine and WB4101. Mol. Pharmacol. 33: 509-514.
Minneman KP and Esbenshade TA (1994) α1-Adrenergic receptor subtypes. Annu. Rev. Pharmacol. Toxicol. 34: 117-133.
Morrow AL and Creese I (1986) Characterization of α1-adrenergic receptor subtypes in rat brain: A reevaluation of [3H]WB4104 and [3H]prazosin binding. Mol. Pharmacol. 29: 321-330.
Muramatsu I (1992) A pharmacological perspective of α1-adrenoceptors: subclassification and functional aspects, in α1-Adrenoceptors (Fujiwara M, Sugimoto T, and Kogure K. ed.), Excerpta Medica Ltd., Tokyo, 193-202.
Muramatsu I, Ohsita M, Ohmura T. Kigoshi S, Akino H, Gobara M. and Okada K (1994) Pharmacological characterization of α1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br. J. Urol. 74:572-577.
Oesterling JE (1995) Benign prostatic hyperplasia, Medical and minimally invasive treatment options. N. Engl. J. Med. 332: 99-109.
Price DT, Lefkowitz RJ, Caron MG, Berkowitz D, and Schwinn DA (1994) Localization of mRNA for three distinctα1-adrenergic receptor subtypes in human tissues: implications for human α1-adrenergic physiology. Mol. Pharmacol. 45: 171-175.
Ramarao CS, Kincade Denker JM, Perez DM, Gaivin RJ, Riek RP, and Graham RM (1992) Genomic organization and expression of the human α1-adrenergic receptor. J. Biol. Chem. 267:21936-21945.
Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Fumess LM, Parry-Smith DJ, Peter B, and Bailey DS (1995) Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues, JPET 272: 134-142.
Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, and Bayne M (1994) Cloning, expression and characterization of human α adrenergic receptors α1A, α1B, and α1C. Biochem. Biophys. Res. Commun. 201:1296-1304.
Weis KA, Epstein RS, Huse DM, Deverka PA and Oster G (1993) The costs of prostatectomy for benign prostatic hyperplasia. Prostate 22: 325-334.
Wennberg JE, Roos N. Soia L, Schori A, and Jaffe R (1987) Use of claims date systems to evaluate health care outcomes: mo

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Arylsubstituted piperazines useful in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arylsubstituted piperazines useful in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylsubstituted piperazines useful in the treatment of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3390019

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.